Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects

A legfontosabb adatok

Ki végzi
University Medical Center Groningen
Hol
Hollandia3 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
939 fő vett részt
Kezdés
2014. júl.
Befejezés
2026. ápr.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • Vena punction
A regiszteradat frissítve
2025. szeptember 15.

Ki vehet részt

Életkor
18 év – 75 év
Nem
Csak férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki nem vehet részt

  • Mental disorder (no informed consent available)
  • Presence of active malignant disease
  • A potential subject who meets any of the following criteria will be excluded from participation in this study:

Egyéb feltételek

  • All participating patients have to meet the following criteria:
  • Alive
  • TC diagnosis between 01-01-1976 to 31-12-2007
  • TC treatment center: UMCG, NKI/AVL, Erasmus MC, UMCN, LUMC
  • Younger than 50 years of age at TC diagnosis
  • Written informed consent; Cases have to fulfill, beside the aforementioned criteria, the following criteria:
  • Diagnosed with either myocardial infarction (MI), proven coronary artery disease (CAD) (CTCAE-4 grade 2 or higher) or congestive heart failure (CHF) (CTCAE-4 grade 2 or higher)
  • No medical history of CVD before diagnosis of TC; In order to be eligible to participate in the cardiometabolic risk inventory study (and to be invited to a study assessment), a subject must meet, next to the criteria mentioned in "1)", the following inclusion criteria:
  • Younger than 40 years of age at TC diagnosis
  • Younger than 75 years of age at moment of inclusion

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Testicular cancer (TC) is a rare disease, which mostly affects young men aged 15-35 years. Their life expectancy has greatly improved due to the introduction of platinum-containing chemotherapy for disseminated TC in the late 1970s. Given the good prognosis of TC nowadays, prevention or early detection of late adverse effects of TC treatment has become increasingly important. Current literature suggests that TC treatment, and specifically exposure to platinum agents, is associated with increased risk of cardiovascular morbidity and mortality. The precise role of treatment components like platinum in the pathogenesis of cardiometabolic changes and cardiovascular disease (CVD) warrants further investigation, since it is not known if CVD develops through direct platinum-induced damage of the vascular wall or by mediation through development of cardiometabolic riskfactors. The aim of this study is to identify risk factors for development for CVD after treatment for TC. A more profound insight into pathophysiologic mechanisms and identification of risk factors for CVDs is needed to facilitate development of preventive strategies and to optimize survivorship care.

A vizsgálat 2 csoportja

  • Cases

    Patients who developed cardiovascular disease after testicular cancer treatment

    Kezelés: Vena punction

  • Subcohort members

    A random selection out of the total cohort of testicular cancer patients per participating hospital

    Kezelés: Vena punction

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Case-cohort Study to Identify Risk Factors for Cardiovascular Disease in Testicular Cancer Survivors
Publikációk
A regiszteradat frissítve
2025. szeptember 15.